M2T-CD33 has received orphan drug designation for AML, offering incentives like tax credits and market exclusivity. The M2T platform is a novel immunotherapy approach targeting CD33-positive leukemic ...
Leukogene Therapeutics has received orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for M2T-CD33 (LTI-214), its immunotherapy candidate targeting acute myeloid leukaemia ...
CHARLESTON, S.C., November 05, 2025--(BUSINESS WIRE)--Leukogene Therapeutics Inc. (LTI), a biopharmaceutical company developing next-generation immunotherapies for hematologic and other malignancies, ...
U.S. FDA Grants Orphan Drug Designation to Leukogene Therapeutics’ M2T-CD33 (LTI-214) for the Treatment of Acute Myeloid Leukemia Leukogene Therapeutics Inc. (LTI), a biopharmaceutical company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback